Back to today’s briefing

Story perspectives

Eli Lilly Acquires Scorpion’s $2.5B Cancer Treatment Program

1/13/2025

24 4

Summary

Story summary

Eli Lilly is making waves in the pharmaceutical world with its bold $2.5 billion acquisition of Scorpion Therapeutics' promising PI3K? inhibitor program, STX-478, aimed at battling mutations in breast and other cancers. As Scorpion pivots to a new company focused on precision medicine, it retains its dedicated team, setting the stage for innovative breakthroughs.

1 of 1

Story summary

Eli Lilly is making waves in the pharmaceutical world with its bold $2.5 billion acquisition of Scorpion Therapeutics' promising PI3K? inhibitor program, STX-478, aimed at battling mutations in breast and other cancers. As Scorpion pivots to a new company focused on precision medicine, it retains its dedicated team, setting the stage for innovative breakthroughs.